ND PHARMA & BIOTECH LTDActive

Company number 08273797Private limited companyIncorporated 2012

Key figures

£211,239,728-0.0%
Net assets 2024/25
+0.1%
Average annual growth 2019/20–2024/25
0100 m200 m300 m2019/202020/212021/222022/232023/242024/25

Like most small UK companies, ND PHARMA & BIOTECH LTD does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Ratios

2024/25
Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
0100 m200 m300 m2019/202020/212021/222022/232023/242024/25
Filed accounts2019/20–2024/25
2020/212021/222022/232023/242024/25
Total assets211,551,315211,551,695211,551,885211,551,885211,551,885
Total liabilities—————
Net assets / total equity211,245,142211,243,242211,242,242211,241,030211,239,728
Average number of employees00000

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Summary: ND PHARMA & BIOTECH LTD

Company

ND PHARMA & BIOTECH LTD is a private limited company registered with Companies House under company number 08273797. It was incorporated on 30 Oct 2012. Its status is active. The registered office is in London (WC2A). Its nature of business (SIC 2007) is manufacture of other chemical products n.e.c. (20590), manufacture of basic pharmaceutical products (21100), manufacture of pharmaceutical preparations (21200), research and experimental development on biotechnology (72110).

Accounts

The latest accounts in the database are for 2024/25 (period ending 31 Oct 2025); the company files small company accounts (filleted). Net assets were £211,239,728, down 0% on the previous year. The company had an average of 0 employees. Figures are available for 6 financial years (2019/20–2024/25).

Control and charges

One person with significant control is registered.

Filing deadlines

The next accounts are due by 31 Jul 2027. The next confirmation statement is due by 31 Oct 2026.